Chiu, Yi-Lin
Rush University Medical Center · Johns Hopkins University · University of Manchester · Dana-Farber Cancer Institute · Cancer Research UK Manchester Institute · University of Colorado Cancer Center · Northwest Medical Specialties · University of California Davis Medical Center · University of California, Davis
2 papers on CoChatORCID 0000-0002-1827-6924
Most cited papers
- Verified
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology
Cell death mechanisms and regulationLymphoma Diagnosis and Treatment
Cited by 876
- Verified
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology
Cell death mechanisms and regulationLung Cancer Research Studies
Cited by 603
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free